04/07/2006
ReGen Therapeutics Plc (‘ReGen’) announces that in the light of recent press comment it is in discussions regarding a licensing agreement for the commercialization of ColostrininTM in North America. These discussions have been in progress for some time.
A further announcement will be made when appropriate.
Further information:
Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile: 07785 297111